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While they account for one-ﬁfth of new cancer cases, rare cancers are difﬁcult to study. A higher than average degree of
uncertainty should be accommodated for clinical as well as for population-based decision making. Rules of rational deci-
sion making in conditions of uncertainty should be rigorously followed and would need widely informative clinical trials. In
principle, any piece of new evidence would need to be exploited in rare cancers. Methodologies to explicitly weigh and
combine all the available evidence should be reﬁned, and the Bayesian logic can be instrumental to this end. Likewise,
Bayesian-design trials may help optimize the low number of patients liable to be enrolled in clinical studies on rare
cancers, as well as adaptive trials in general, with their inherent potential of ﬂexibility when properly applied. While clinical
studies are the mainstay to test hypotheses, the potential of electronic patient records should be exploited to generate
new hypotheses, to create external controls for future studies (when internal controls are unpractical), to study effective-
ness of new treatments in real conditions. Framework study protocols in speciﬁc rare cancers to sequentially test sets of
new agents, as from the early post-phase I development stage, should be encouraged. Also the compassionate and the
off-label settings should be exploited to generate new evidence, and ﬂexible regulatory innovations such as adaptive
licensing could convey new agents early to rare cancer patients, while generating evidence. Though validation of surro-
gate end points is problematic in rare cancers, the use of an updated notion of tumor response may be of great value in
the single patient to optimize the use of therapies, all the more the new ones. Disease-based communities, involving clini-
cians and patients, should be regularly consulted by regulatory bodies when setting their policies on drug approval and
reimbursement in speciﬁc rare cancers.
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introduction
These recommendations were worked out through a multidis-
ciplinary and multistakeholder consensus process, promoted by
‘Rare Cancers Europe’ (RCE). They are proposed to the health
and research communities as a contribution to improve clinical
studies about rare cancers, given the peculiar difﬁculties they pose.
The ultimate goal is to make sure that rare cancer patients are not
discriminated against because of the rarity of their diseases.
Having regard to the area of clinical research, they expand
Political Recommendations on rare cancers (http://www.
rarecancerseurope.org) selected in 2008 as the founding basis
for RCE. RCE is a multistakeholder initiative dedicated to
putting rare cancers ﬁrmly on the European policy agenda, ad-
vancing the way rare cancer patients are diagnosed and treated
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in Europe, and improving translational and clinical research on
rare cancers.
basic considerations
• Rare cancers account for as many as 20% of new cancer cases
[1]. According to conventional methodologies, clinical trials
need considerable numbers of patients that are difﬁcult to
collect in rare cancers. By deﬁnition, therefore, clinical evidence
is more difﬁcult to build in rare than in frequent cancers.
• Efforts to set up large collaborative clinical trials merit special
attention in rare cancers. Collaborative networking is crucial
and needs to be funded properly. However, the limiting factor
of large collaborations may be a lack of clinical expertise.
In principle, inappropriate clinical performance might ﬂaw
the outcome of a clinical trial to the same extent as methodo-
logical biases.
• It follows that alternative ways to conceive study design, ana-
lysis of data and combination of results would be exceedingly
important. It is possible that some innovative solutions may
imply a price to pay in terms of a higher uncertainty. However,
discriminations in rare cancer patients’ access to effective care
are inevitable, if a higher degree of uncertainty is not accepted
when compared with more frequent conditions.
clinical decision making in rare cancers
1) The problem of rare cancers is one of a higher uncertainty.
By no means does this imply that decision making in rare
cancers should be conceptually different from that in more
frequent conditions. As usual, it is crucial for the clinician to
address decision making rationally. In the language of deci-
sion theory, this means to properly manage ‘probabilities’
and ‘utilities’ [2]. Also in rare tumors, therefore, an effort
should be made to shape the results of clinical research in
such a way that they provide the physician, and the patient,
with informative probability distributions on major expected
outcomes, with the central value corresponding to the ‘risk’
and the distribution representing the ‘uncertainty’ thereof,
and, when probability curves as a function of time are avail-
able, with their full shape over time made understandable.
Patient’s ‘attitude toward risk’ should be taken into account
for an individualized decision making.
2) Likewise, quality of life should be incorporated as much as
possible as an end point also in clinical studies on rare
cancers, with the aim to let the physician describe it as pre-
cisely as possible at the patient’s bedside, in order to elicit in-
dividual patient’s utilities factoring their individual values
and preferences.
3) Third payers, regulatory agencies and local health systems
should avoid discriminations against rare cancer patients.
The cost/efﬁcacy thresholds used by any third payer for deci-
sions on resource allocation can well be the same as for fre-
quent cancers, but the uncertainty on quantiﬁcation should
be accepted as possibly higher in rare cancers. This also
applies to deﬁnition of state of the art through clinical prac-
tice guidelines, and the like.
4) Rare cancer patients often argue in favor of relaxing the
usual risk-averse attitude of medical decisions [3]. In fact,
under an individual perspective, the trade-off between risks
of side-effects deriving from a new treatment and the cer-
tainty of progressive cancer is often solved, rationally, by
choosing to try the new treatment. To a reasonable extent,
this should be taken into consideration also by regulatory
bodies when assessing the risk/beneﬁt ratio of new treat-
ments in bad prognosis scenarios.
5) Innovative approaches to summarize available evidence
should be encouraged [4]. They should allow to make the
most of all available knowledge, which is particularly critical
when the direct experimental evidence is scanty, or of sub-
optimal methodological quality. The principles of systematic
reviews should be followed. In addition to randomized clinical
trials, also preclinical evidence, as well as uncontrolled trials,
observational studies and analyses of retrospective case series,
or anecdotal cases, should be considered when summarizing
the available evidence. Medical journals should consider the
rarity of diseases when shaping their editorial policies, to make
sure that any additional evidence is made available. Especially
in the case of very rare cancers, even evidence from similar dis-
eases can be taken into consideration. A degree of subjectivity
is inevitable under this approach. However, formal method-
ologies can be followed and consensus processes can be put in
place, in an effort to reduce subjectivity. It has been proposed
to score available studies for their validity and pertinence [5].
Validity of studies is based on their design (randomized or un-
controlled, prospective or retrospective etc.) and their quality
(presence of ﬂaws in a randomized trial, existence of prespeci-
ﬁed external controls in an uncontrolled trial etc.). Pertinence
is scored according to how much the study focused on the
same disease, the same treatment, the same patient subgroup,
and the like. Consensus processes should be put in place to
generate such scores. Methodologies should be developed to
this end. However, since scores would be made explicit, the
assumptions of all conclusions could be publicly reviewed
and discussed. Likewise, sensitivity analyses could be made to
evaluate to which extent conclusions are sensitive to the
assumptions and arbitrary values incorporated in the model
(i.e. by assessing how the ﬁnal probability distributions are
affected by changes in these assumptions and values).
study designs in rare cancers
1) Clinical studies on drugs are classically divided into phases,
according to their primary objective: deﬁnition of the
optimal dose for phase I, drug activity for phase II and efﬁ-
cacy for phase III [6]. In rare cancers, where large trials may
be unfeasible, the methodology of phase II uncontrolled
studies has often been applied to trials whose aim was
indeed to explore efﬁcacy, not simply antitumor activity. On
the contrary, an effort should be made: (i) to identify and
clearly express the true aim(s) of each trial, in order to avoid
ambiguities that may compromise its validity and hamper
the unequivocal interpretation of its results; (ii) to adopt the
methodologies that are appropriate for these aim(s) or,
whenever this is not possible, to acknowledge the suboptimal
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methodology of the trial while accounting for its limitations
in its analysis and interpretation.
2) When the enrollment in a study of an adequate number of
eligible patients is not feasible, an option is to carry out low-
power randomized clinical trials [7]. In this way, the prin-
ciple of internal controls is met, and the biases from uncon-
trolled studies are avoided. However, the risk of missing a
moderate/small treatment effect is high, and the low power
of the trial should be acknowledged in the study protocol.
The minimum difference for which good power is met
should be made explicit in the protocol, as well as the actual
power for the expected minimum difference of clinical inter-
est. This may allow reviewing committees to make informed
decisions as to the added value of a new study.
3) Research on biomarkers should be an inherent part of re-
search on new drugs, because it may help identify those
patient populations in which the drug is able to provide re-
markable beneﬁts. Clinical studies into these selected patient
populations are exposed to all problems of rare diseases, but
the sample size can be lower if the expected difference is
high, and a sufﬁcient power to detect this difference can be
attained even with a reasonably low number of patients. In
principle, studies on small selected populations where large
beneﬁts are expected should always be preferred to large
studies on unselected populations where moderate or small
beneﬁts are expected. Regulatory bodies should encourage
clinical studies seeking large beneﬁts, even if the target popu-
lations are small, possibly tolerating a higher degree of un-
certainty as a result of the paucity of eligible patients [8].
Statistical signiﬁcance per se should never be the only factor
to be considered for regulatory/reimbursement as well as
clinical purposes [9]. The most likely magnitude of beneﬁt
should be regarded as a key factor for any decision.
4) If the choice is made not to plan a trial with an internal
control arm, external controls must be used. Controlled
studies are usually felt to be unnecessary (or unethical)
when: (i) dramatic beneﬁcial effects (e.g. cure) are likely, al-
though in a minority of patients, in the lack of effective alter-
natives; (ii) an important and frequent beneﬁcial effect was
seen in a series of patients, in the presence of a clear-cut
mechanism of action of the treatment; (iii) there is universal
consensus on the lack of equipoise. Stringent methodological
requirements are needed, including: rigorous patient selec-
tion criteria; record of refusals (inasmuch as the intent-to-
treat principle is even more important); identiﬁcation of ex-
ternal controls in the protocol before any analysis; formaliza-
tion of statistical considerations as in a conventional
randomized trial; proper selection of end points (response,
duration of response, survival). The problem of ‘stage migra-
tion’ with historical controls is particularly important, and
the introduction of new biomarkers may amplify it.
5) Adaptive trials allow to change aspects of the study while
this is ongoing, depending on analyses of data obtained from
patients enrolled in the same or other studies [10]. Rare
cancers take special beneﬁt from adaptive trials, because of
the difﬁculty to ﬁnd patients for clinical studies and the con-
sequently long recruitment timelines. The development of a
new drug, all the more in rare cancers, can be easier and
faster thanks to adaptive mechanisms, such as, for example,
the intensive use of stopping rules, the transformation of a
phase II into a phase III study (‘seamless phase II/III
designs’) in case the early stage of the study was positive, or
the use of ‘drop-the-loser’ or ‘play-the-winner’ designs.
Appropriate statistical techniques are available to handle the
following adaptations: (i) adaptations of eligibility criteria
based on results of the same or other studies, or difﬁculties in
recruitment etc.; (ii) unexpected deviations from hypothe-
sized base risks and event occurrences; (iii) stopping rules
for futility or safety reasons; (iv) changes in data analysis
based on accumulating external evidence [11]. Other
mechanisms are considered to be more problematic, such as
all those based on unblinded interim analyses of efﬁcacy.
Obstacles to adaptive designs may be the duration of treat-
ment, as well as the time to treatment effects and use of sur-
rogate end points. Thus, the use of adaptive mechanisms
should be accurately planned by the clinical researcher and
the statistician, and speciﬁed in the study protocol.
Availability of an effective data monitoring committee is crit-
ical. However, it is recommended to make efforts to assess
the feasibility of adaptive designs when planning clinical
studies in rare cancers. Likewise, it is recommended that
methodological research is promoted to address the pro-
blems still faced with adaptive studies.
6) The conventional frequentist approach to clinical studies is
focused on the control of the probability of false-positive
results under the null hypothesis of no treatment effect (type
I error) and on the probability of a false-negative result
under an alternative, prespeciﬁed hypothesis of treatment ef-
ﬁcacy (type II error). The ‘P value’ represents the probability
of observed (or more extreme) results in the case the null hy-
pothesis were true. On the contrary, Bayesian-design trials
are marked by the use of a prior probability distribution and
the generation of a posterior probability distribution of the
treatment effect [5, 12, 13]. Bayesian analyses produce prob-
ability distributions of the treatment effect, that is, estimates
of the probability that the true treatment effect lies between
any two values (e.g. that the risk reduction is between 10%
and 20% etc.) or is below or above any speciﬁed threshold (e.
g. a risk reduction <5%, >30% etc.). To use Bayesian method-
ologies, evidence available outside the trial needs to be con-
sidered, not only in planning the trial, but also in its analysis
and interpretation. In Bayesian trials, there is not a pre-ﬁxed
number of patients to enroll, the target number of patient
being dictated by the desired precision of the summary esti-
mate of treatment effect, i.e. the width of the range of its
plausible values. Furthermore, probability distributions pro-
vided by a Bayesian analysis can be directly used by the clin-
ician in the clinical decision-making process, e.g. within a
formal decision analysis. The main weakness of the Bayesian
approach is the dependence of its conclusions on the prior
probability distribution, whose deﬁnition entails an arbitrary,
though not necessarily subjective, component. In general, con-
sensus mechanisms should be arranged before setting up a
Bayesian study in a transparent way to elicit prior probability
distributions, and sensitivity analyses should be foreseen.
7) Efﬁcacy is generally intended as an average effect observed
under ideal conditions, i.e. in a clinical trial, which may well
be different from what happens in real conditions, i.e. in the
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actual clinical practice. This is often called ‘effectiveness’. In
this sense, there may be an issue about the generalizability of
a trial on a new treatment, i.e. as to which extent efﬁcacy
demonstrated in the trial can be converted into effectiveness
in real life. However, clinical research is done to improve
clinical practice, which then has to change according to the
new results of research. Therefore, the lack of generalizability
of a new treatment when a trial has shown its superiority
should be properly addressed by ﬁnding ways to transfer it
into clinical practice and should not be viewed as an obstacle
in principle to the introduction of the new treatment. This is
all the more true of rare cancers, where the expertise is less
accessible and the driving force of the market is lower to
attract for-proﬁt players.
8) It has been claimed that the availability of electronic patient
records, which can be connected through wide data networks,
gives rise to the opportunity to measure effectiveness in real
conditions. Particularly in rare and very rare cancers, the sub-
stantial amount of data generated thereby is felt as a great op-
portunity to evaluate the effectiveness of available treatments
in real conditions. In principle, there is no qualitative differ-
ence between the efﬁcacy and the effectiveness of a new treat-
ment, and the latter simply represents the actual translation in
real conditions of the former, which in a sense is an ‘unob-
servable’ property of the treatment. Therefore, the same biases
which hamper the estimation of efﬁcacy outside a formal trial
(and also within trials) prevent the use of routine clinical data
to provide unbiased estimates of effectiveness. In other words,
estimates of treatment effectiveness obtained from observa-
tional studies are exposed to major biases, and the statistical
methods used to adjust imbalances in baseline factors cannot
take into account unknown or unmeasured confounders, and
therefore cannot assure that patients who received different
treatments are actually comparable. As a consequence, clinical
data extracted from current clinical practice can be used: (i) to
provide information of the appropriateness of patient man-
agement in the real world, through the use of indicators con-
sisting of surrogate end points (e.g. response rate etc.) and of
markers of quality of care (e.g. early mortality etc.); (ii) to gen-
erate speciﬁc hypotheses to be tested in future trials (e.g. on
treatment efﬁcacy in speciﬁc subgroups); (iii) to create histor-
ical series of consecutive, unselected patients that provide in-
formation on time trends in prognosis and occurrence of
speciﬁc outcomes in the general population. These series can
be used as controls in subsequent uncontrolled studies, or to
compare periods where different treatment approaches were
used, whenever radical prognostic changes due to the intro-
duction of a new treatment are assumed to be plausible.
surrogate end points in rare cancers
1) Surrogate end points are those which can replace the natural
clinical end points by having the property of being measured
sooner and/or easier (e.g. relapse-free survival, in the adju-
vant setting, or progression-free survival, in the advanced).
In addition, their effect may be ampliﬁed in comparison to
natural end points (e.g. differences in tumor response are
likely to be of a higher magnitude than corresponding
differences in survival). However, they require to be validated
in order to be used appropriately [14]. Validation needs high
numbers, which are the problem of rare cancers. On the
other hand, sometimes surrogate end points can be the only
way to show improvements timely. In addition, some of
them may recapitulate properties which might be perceived
by patients as a value in se, as, for example freedom from
progression or freedom from relapse inasmuch as quality of
life is concerned, so that they may not require any formal
validation in speciﬁc presentations. A new treatment could
also be used temporarily, under the assumption that the sur-
rogate end point is valid, while waiting for ﬁnal results.
2) While validation of surrogate end points is problematic in
rare cancers, their use is of great value in the clinic, as a tool
to better describe and evaluate treatment beneﬁts at the
patient’s bedside, and also to modulate therapies.
Conceptually, any beneﬁt in terms of antitumor activity actu-
ally observed in the individual patient increases the likeli-
hood of an efﬁcacy advantage in that patient (e.g. a patient
who responds to a medical therapy is more likely to take
some beneﬁt on a longer time span, in comparison to a non-
responding patient). Therefore, a given treatment could be
administered for a short time span and continued only pro-
vided a short-term effect on a surrogate end point, such as
any kind of ‘tumor response’, is observed. This may be rele-
vant to overcome regulatory and reimbursement limitations
to patient access to new treatments in rare cancers. For
example ‘pay-by-result’ approaches, and the like, may well
help optimize cost/efﬁcacy on a population basis.
3) Tumor response is the most typical indicator of antitumor
activity. Unfortunately, it was originally conceived as a di-
chotomous tool to screen drugs worth testing in a phase III
setting, essentially aiming at its reproducibility [15, 16]. This
may explain its limitations as a surrogate end point for clinic-
al efﬁcacy. Currently, an additional difﬁculty is given by the
possibly nondimensional nature of tumor response to many
molecularly targeted agents, while standard response criteria
are mainly based on tumor shrinkage. Sometimes, they may
slow down tumor progression, though progression is not
avoided, so that tumor response and progression-free inter-
vals may not be ﬁt to render the whole potential beneﬁt of
the drug. It is recommended that methodological research
addresses the problem of tumor response in medical oncol-
ogy, trying to redeﬁne it as an indicator which may have clin-
ical meaning, in addition to being reproducible. Modern
medical imaging, including functional imaging, should be
fully exploited. Given the mechanism of action of new mo-
lecularly targeted drugs, nondichotomous deﬁnitions of
tumor response may be useful, as well as those catching the
impact on the growth rate of the tumor [17].
critical organizational aspects of clinical
research in rare cancers
1) Collaborative health care ‘reference networks’ involving
centers of expertise along with other centers able to provide
good quality of care are a crucial instrument to improve
quality of care in the ﬁeld of rare cancers [18]. Quality
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control programs should be in place in order to make sure
that quality of care is evenly distributed across the network.
Reference networks on rare cancers improve health care
and improve accrual in trials, as well as clinical quality
within clinical trials.
2) Patient information about trials should be made widely
available. Patients should be aware that there is always an
added value in entering a trial. On the other side, patient
communities should be involved as much as possible in the
conception of new clinical trials, particularly in regard to
study design and the selection of study end points.
3) Rare cancer trials need to be rich in information in order to
maximize their efﬁciency. For example a long follow-up for
each patient would be crucial to generate information on
the natural history of the disease etc. This applies also to
biological information. Limitations to the duration of
follow-up of patients enrolled in clinical trials should be
overcome. Likewise, limitations to the opportunity to share
the results across trials should be overcome. Efforts should
be made toward clinical trial database sharing [19].
Regulations, including those on data protection, should
remove obstacles. New models regarding ‘precompetitive
collaborations’ and in general collaboration across pharma
companies, should be explored.
4) The review of pathologic diagnosis, if not made at reference
centers, is crucial in rare cancers, to make sure that the
quality of care is high [20, 21, 22]. This obviously applies to
clinical trials and to clinical databases suitable to be used
for retrospective research. Telepathology, expert panels,
dedicated training facilities are useful tools in this direction.
5) There have been patient-driven efforts to feed databases of
studies and of cancer registries, which may become a for-
midable tool to gain new knowledge in rare conditions.
This implies methodological challenges, which should be
addressed.
6) Incentives for orphan drugs encourage pharmaceutical
companies to launch clinical studies on new agents in rare
cancers. However, given the inherently low number of
patients, the risk of failing approval due to lack of evidence
may all the same discourage from developing drugs in most
rare cancers. In addition, screening of new drugs in rare
cancers is by deﬁnition less likely to happen, since phase I
studies will privilege frequent cancers (more likely to be en-
rolled in comparison to any single rare cancer in any phase
I study), and hints of activity from the phase I setting will
be therefore lacking in rare cancers. It is recommended that
mechanisms are put in place to regularly screen new drugs
also in rare cancers. This could be achieved through formal
collaborations among reference centers by using frame-
work study protocols on speciﬁc rare cancers liable to be
exploited to test sequentially new drugs in their phase II
stage of development. Bayesian approaches could be used,
in order to efﬁciently formalize probabilities of activity for
new agents in speciﬁc rare cancers. Mechanisms of condi-
tional approval and ‘adaptive licensing’ should be actively
exploited, because theymay allow rare cancer patients earlier
access to drugs with potentials of efﬁcacy and at the same
time generate new evidence [23]. For this use of new drugs,
patients should be referred to centers and networks of
expertise, scientiﬁc and ethical scrutiny should be arranged
and publication of all results should be foreseen.
7) The compassionate and off-label use of new drugs is more
widespread in rare cancers [24]. Regulations thereof should
be harmonized as much as possible, by acknowledging the
likelihood that orphan indications may not be properly and
timely covered by approval and reimbursement. In return
for some relaxation in rules on compassionate and off-label
use of drugs in rare cancers, this could be exploited to gen-
erate data in ways close to what is done in formal clinical
studies. Also for this use of new drugs, patients should be
referred to centers and networks of expertise, scientiﬁc and
ethical scrutiny should be arranged and publication of all
results should be foreseen.
8) In rare cancers, national, international, even global colla-
borations should be pursued to make investigator-driven
studies possible. These are vital, for example to provide
hints of activity of new agents in very rare cancers, which
could be tested within industry-sponsored trials in case of a
positive result from early low-cost studies. They are vital
also to assess the value of new treatment strategies, with
special regard to multidisciplinary approaches. Currently,
the main obstacles to investigator-driven wide collabora-
tions are regulatory and need to be overcome as much as
possible.
9) Biobanks for medical research are crucial to advance the de-
velopment of new treatments in rare cancers. They should be
maintained by dedicated personnel in a centralized way, to
realize good quality control, proper access, regulatory and
ethical competence and harmonization and standardization.
Currently, major obstacles have to do with data protection.
While data conﬁdentiality needs to be protected by putting
in place all reasonable available means, the right of patients
to donate their tissues for research, if they will, should be
protected as well. The patient should be able to give a ‘broad
consent’ for his/her data and tissues to be used for research
purposes by the treating institutions, avoiding the need to re-
consent whenever a new retrospective research is decided
[25, 26]. Of course, proper ethics and scientiﬁc reviewing
mechanisms for new researches should be in place.
10) In rare cancers, all cases may be useful to advance science.
Thus, prospective clinical databases, registries and connec-
tion of electronic patient records on a network basis should
be encouraged. Collaborative reference networks focusing
on health care should be implemented and properly funded
for quality of care reasons, but their added value in terms of
generating new evidence should always be factored.
11) Cancer registries are essential because they provide vital
data on incidence, prevalence and survival. Population
cancer registries may allow to conduct high-resolution
studies on selected topics. Proper derogations from the re-
quirement of patient’s informed consent are needed for
population-based cancer registries to survive as crucial
public health facilities [27].
12) Observational clinical studies on selected patient subgroups
should be encouraged, because they can allow to gain vital
information on the natural history and clinical characteristics
of entities which sometimes are described only pathological-
ly, and can generate external controls for uncontrolled
 | Casali et al. Volume 26 | No. 2 | February 2015
reviews Annals of Oncology
 at U








clinical studies. Data generated by health care databases
should be exploited, overcoming unneeded regulatory con-
straints.
13) Given the key role played by regulatory bodies through
their scientiﬁc advices to pharmaceutical companies
embarking into development of new drugs in cancers,
regular consultations between these bodies and the rare
cancer-based communities (both patient- and physician-
driven) would be vital to tailor the way new drugs are devel-
oped in rare cancers. Conﬁdentiality issues and conﬂicts of
interest should be managed. In principle, the value of the
disease-based communities should be acknowledged and
regulatory/reimbursement bodies should view them as
active partners in establishing criteria for approval of new
treatments in rare cancers.
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